STANDARD BIOTOOLS INC
Standard BioTools Inc (ticker: LAB) develops and sells instruments, reagents and software used in life‑science research and molecular diagnostics. The company’s platforms are deployed with academic researchers, pharmaceutical and biotechnology organisations and clinical laboratories. With a market capitalisation of about $504.2m, it is a smaller‑cap participant in the life‑sciences tools segment; that size can result in greater share‑price volatility and sensitivity to research and industry capital expenditure cycles. Key investment considerations include the proportion of recurring consumables revenue, the timing of instrument orders, competitive pressure from larger vendors and any regulatory matters tied to diagnostic use. Financial results can be uneven as customers delay or accelerate spending, and technology shifts can alter the competitive landscape. Investors should view this as a growth‑oriented, higher‑risk exposure within healthcare tools, review recent financials and cash flow, and seek independent advice tailored to their circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Standard Biotools Inc. stock with a target price of $1.55, indicating growth potential.
Financial Health
Standard Biotools Inc is performing well with strong revenue and cash flow, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring LAB
Activist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore Basket3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth Drivers
Recurring consumables and adoption of analytical platforms can support revenue growth, though demand may fluctuate with research funding and capital budgets.
Customer Mix
Customers include academic, biopharma and clinical labs worldwide; partnerships and institutional purchasing matter, but priorities and funding can vary.
Tech & Competition
Product innovation can create advantage, yet larger competitors and rapid technological change mean outcomes and performance can vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
